IDEAYA Biosciences (IDYA) Total Current Liabilities (2018 - 2026)

IDEAYA Biosciences has reported Total Current Liabilities for 9 years, with the latest figure at $64.8 million in Q1 2026.

• Quarterly Total Current Liabilities rose 27.5% year-over-year to $64.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.8 million (up 27.5% YoY) and the FY2025 annual result came in at $58.8 million, up 27.66% from the prior year.
• Total Current Liabilities improved to $64.8 million in Q1 2026 per IDYA's latest filing, from $58.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $64.8 million in Q1 2026 and troughed at $24.9 million in Q3 2023.
• A 5-year average of $43.1 million and a median of $40.7 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities plunged 56.38% in 2023, then soared 103.71% in 2025.
• Over 5 years, Total Current Liabilities stood at $31.7 million in 2022, then declined by 14.56% to $27.1 million in 2023, then jumped by 70.0% to $46.1 million in 2024, then grew by 27.66% to $58.8 million in 2025, then increased by 10.23% to $64.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $64.8 million, $58.8 million, and $64.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.